跳至主要内容
临床试验/NCT01491100
NCT01491100已完成不适用

Study Assessing Cognitive Performance Plus Physical Activity in Patients With Relapsing-Remitting MS Under Treatment With Betaferon®

Bayer0 个研究点目标入组 1,085 人开始时间: 2012年4月30日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
发起方
Bayer
入组人数
1,085
主要终点
Cognitive performance as measured by SDMT (Symbol Digit Modalities Test)

研究概览

简要总结

Study assessing cognitive function and physical activity in people with relapsing remitting multiple sclerosis.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
12 Years 至 70 Years(Child, Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients with Relapsing Remitting Multiple Sclerosis (RRMS), and treated with Betaferon, with the decision for treatment made at the discretion of the attending physician, documented with a prescription of Betaferon by the physician
  • EDSS 0 - 6
  • Written informed consent

排除标准

  • Patients who do not meet the local indication criteria for Betaferon treatment.
  • Contraindications listed in the local SmPCs have to be considered.
  • Patients with a history of severe head trauma.
  • Patients with alcohol and/or drug abuse.
  • Patients with mental retardation.
  • Patients with learning disability.

研究组 & 干预措施

Group 1

干预措施: Interferon beta-1b (Betaseron, BAY86-5046) (Drug)

结局指标

主要结局

Cognitive performance as measured by SDMT (Symbol Digit Modalities Test)

时间窗: 24 months

Physical activity as measured by the Baecke questionnaire

时间窗: 24 months

次要结局

  • Disability as measured by EDSS (Expanded Disability Status Scale)(24 months)
  • Fatigue as measured by FSMC (Fatigue Scale for Motor and Cognitive Functions)(24 months)
  • Depression as measured by the CES-D (Center for Epidemiologic Studies Depression)(24 months)
  • Quality of life as measured by the SF-12 (Mental and physical health-scale measure of quality of life)(24 months)

研究者

发起方
Bayer
申办方类型
Industry
责任方
Sponsor

相似试验